Synergistic in vitro antiretroviral activity of a humanized monoclonal anti-CD4 antibody (TNX-355) and enfuvirtide (T-20)

Antimicrobial Agents and Chemotherapy

Volumn 50, Issue 6, 2006, Pages 2231-2233

  Zhang, Xing Quan ^a   Sorensen, Meredith ^b   Fung, Michael ^c   Schooley, Robert T ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

^c Tanox Biosystems Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ENFUVIRTIDE; TNX 355;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG POTENTIATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IC 50; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; VIRUS CELL INTERACTION; VIRUS REPLICATION;

ANTI-RETROVIRAL AGENTS; ANTIBODIES, MONOCLONAL; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV-1; HUMANS; INHIBITORY CONCENTRATION 50; LEUKOCYTES, MONONUCLEAR; PEPTIDE FRAGMENTS;

EID: 33744492607     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00761-05     Document Type: Article

References (16)

1. Boon, L., B. Holland, W. Gordon, P. Liu, F. Shiau, W. Shanahan, K. A. Reimann, and M. Fung. 2002. Development of anti-CD4 MAb hu5A8 for treatment of HIV-I infection: preclinical assessment in non-human primates. Toxicology 172:191-203.
2. Burkly, L. C., D. Olson, R. Shapiro, G. Winkler, J. J. Rosa, D. W. Thomas, C. Williams, and P. Chisholm. 1992. Inhibition of HIV infection by a novel CD4 domain 2-specific monoclonal antibody: Dissecting the basis for its inhibitory effect on HIV-induced cell fusion. J. Immunol. 149:1779-1787.
3. Chou T.-C. 1991. The median-effect principle and the combination index for quantitation of synergism and antagonism, p. 61-102. In T.-C. Chou and D. C. Rideout (ed.), Synergism and antagonism in chemotherapy. Academic Press, San Diego, Calif.
4. Kuritzkes, D. R., J. Jacobson, W. G. Powderly, E. Godofsky, E. DeJesus, F. Haas, K. A. Reimann, J. L. Larson, P. O. Yarbough, V. Curt, and W. R. Shanahan, Jr. 2004. Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1. J. Infect. Dis. 189:286-291.
5. Lalezari, J. P., K. Henry, M. O'Hearn, J. S. Montaner, P. J. Piliero, B. Trottier, S. Walmsley, C. Cohen, D. R. Kuritzkes, J. J. Eron, Jr., J. Chung, R. DeMasi, L. Donatacci, C. Drobnes, J. Delehanty, and M. Salgo. 2003. TORO 1 Study Group. Enfuvirtide, an HIV-I fusion inhibitor, for drug-resistant HIV infection in North and South America. N. Engl. J. Med. 348:2175-2185.
6. Lazzarin, A., B. Clotet, D. Cooper, J. Reynes, K. Arasteh, M. Nelson, C. Katlama, H. J. Stellbrink, J. F. Delfraissy, J. Lange, L. Huson, R. DeMasi, C. Wat, J. Delehanty, C. Drobnes, and M. Salgo. 2003. TORO 2 Study Group. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N. Engl. J. Med. 348:2186-2195.
7. + cells. J. Virol. 66:4784-4793.
8. Palella, F. J., K. M. Delaney, A. C. Moorman, M. O. Loveless, J. Fuhrer, G. A. Satten, D. J. Aschman, and S. D. Holmberg. 1998. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N. Engl. J. Med. 338:853-860.
9. Reimann, K. A., L. C. Burkly, B. Burrus, B. C. Waite, C. I. Lord, and N. L. Levin. 1993. In vivo administration to rhesus monkeys of a CD4-specific monoclonal antibody capable of blocking AIDS virus replication. AIDS Res. Hum. Retrovir. 9:199-207.
10. Reimann, K. A., R. L. Cate, Y. Wu, L. Palmer, D. Olson, B. C. Waite, N. L. Levin, and L. C. Burkly. 1995. In vivo administration of CD4-specific monoclonal antibody: effect on provirus load in rhesus monkeys chronically infected with the simian immunodeficiency virus of macaques. AIDS Res. Hum. Retrovir. 11:517-525.
11. Reimann, K. A., R. Khunkhun, W. Lin, W. Gordon, and M. Fung. 2002. A humanized, non-depleting anti-CD4 antibody that blocks virus entry inhibits virus replication in Rhesus monkeys chronically infected with simian immunodeficiency virus. AIDS Res. Hum. Retrovir. 18:747-755.
12. Reimann, K. A., W. Lin, S. Bixler, B. Browning, B. N. Ehrenfels, J. Lucci, K. Miatkowski, D. Olson, T. H. Parish, M. D. Rosa, F. B. Oleson, Y. M. Hsu, E. A. Padlan, N. L. Levin, and L. C. Burkly. 1997. A humanized form of a CD4-specific monoclonal antibody exhibits decreased antigenicity and prolonged plasma half-life in rhesus monkeys while retaining its unique biological and antiviral properties. AIDS Res. Hum. Retrovir. 13:933-943.
13. Reynes, J., R. Rouzier, T. Kanouni, V. Baillat, B. Baroudy, A. Keung, C. Hogan, M. Markowitz, and M. Laughlin. 2002. SCH-C: safety and antiviral effects of a CCR5 receptor antagonist in HIV-I infected subjects. In Ninth Conference on Retroviruses and Opportunistic Infections. [Online.] http: //www. retroconference.org/2002/Abstract/14090.htm.
14. Schols, D., S. Claes, E. De Clercq, C. Hendrix, G. Bridger, G. Calandra, G. Henson, S. Fransen, W. Huang, J. M. Whitcomb, and C. J. Petropoulos for the AMD-3100 HIV Study Group. 2002. AMD-3100, a CXCR4 antagonist, reduced viral load and X4 virus levels in humans. In Ninth Conference on Retroviruses and Opportunistic Infections. [Online.] http://www .retroconference.org/2002/ Abstract/13443.htm.
15. Tremblay, C. L., F. Giguel, C. Kollmann, Y. Guan, T. C. Chou, and B. M. Baroudy. 2002. Anti-human immunodeficiency virus interactions of SCH-C (SCH 351125) and, a CCR5 antagonist, with other antiretroviral agents in vitro. Antimicrob. Agents Chemother. 46:1336-1339.
16. Tremblay, C. L., C. Kollmann, C. F. Giguel, T. C. Chou, and M. S. Hirsch. 2000. Strong in vitro synergy between the fusion inhibitor T-20 and the CXCR4 blocker AMD 3100. J. Acquir. Immune Defic. Syndr. 25:99-102.